Try our Advanced Search for more refined results
Life Sciences - May, 2023
350 articles
- Abbott Says Ex-Nutrition Scientist Is Peddling Trade Secrets
- J&J Defends Talc Powder As 1st Post-Spinoff Trial Begins
- Mallinckrodt Can't Get Out Of Manhattan Project Waste Suit
- FDA Cracks Down On Illegal Sales Of Disposable E-Cigs
- Genentech Urges End To 'Threadbare' 401(k) Fees Suit
- Crowell & Moring Barred From Humana Case, Walgreens Says
- NC Manufacturer To Disband Amid Mountain Of Benzene Suits
- Why Fed. Circ. Should Explain Treatment Of Prior Art Ranges
- Stryker Loses Challenges To OsteoMed Patents At PTAB
- Neurosurgeon Says Partner In Med Tech Startup Hid Fraud
- A Watershed Moment For Microbiome-Based Therapy
- Nixon Peabody Taps Longtime Partner As Albany Office Head
- Legal Pitfalls To Watch For When Advertising Psychedelics
- Bayer Calls Whistleblower's Ex-Attys' Fee Bids Excessive
- Ex-FBI Trainee's Friend Liable In Stolen Stock Tips Suit
- Teva's Drug IP Deal With Gilead Not Pay To Delay, Jurors Hear
- Acthar Buyers Still Want Class Treatment In Antitrust Suit
- US Goes After Counterfeit Drug Labeling With New Sanctions
- Pfizer, Ex-Execs Say Trade Secrets Row Close To Being Settled
- Alnylam Widens Vaccine IP Litigation Against Pfizer, Moderna
- Real Estate Rumors: Popular Bank, Nuveen, Madison Capital
- Former FDA Officials Say Fosamax Claims Aren't Barred
- Elizabeth Holmes Begins 11-Year Prison Sentence In Texas
- Trending At The PTAB: IPR Estoppel After Ironburg
- Takeaways From New Fla. Pharmacy Benefit Manager Rules
- Federal Restrictions On Phthalates Are Long Overdue
- Suboxone Buyers Fight Late Dismissal Bid In Antitrust Case
- Amarin Legal Head Earned $2.6M Package In '22
- LabMD Agrees To Arbitrate Malpractice, Fraud Claims
- J&J Says New Ch. 11 Would Be Largest Settlement In History
- Justices Pass On Ex-Shkreli Attorney's Restitution Appeal
- 2 Firms Guide Anew Medical's $94M SPAC Merger
- 2nd Circ. Upholds Sackler Releases In Purdue Ch. 11 Plan
- Lilly To Pay $13M, Cap Insulin Cost In Deal Worth Up To $500M
- Court Temporarily Blocks SC Abortion Ban
- Evidence Should Shred Glycine Evasion Ruling, Importers Say
- Judge Won't Sink FCA Suit Over Medical Kickback Scheme
- Investor Activist Campaigns Heat Up Just In Time For Summer
- Ex-Fed. Circ. Chief Backs Another Patent Eligibility Case
- Fed. Circ. Backs ITC In Surgical Stapler IP Row
- DEA Targets Opioid Distributor Over 'Egregious Failures'
- Looking For Plausibility In FTC's Amgen Merger Challenge
- TCPA Protects Cellphone Users, Michigan Panel Rules
- Some Client Speculations On AI And The Law Firm Biz Model
- FDA Warns Cos. Of Potential Vape Product Violations
- UK Litigation Roundup: Here's What You Missed In London
- Chevron Deference In Limelight As DeSantis Joins 2024 Race
- SC's 6-Week Abortion Ban Violates Privacy, Challengers Say
- Amentum Says Exercise Company Atty Intimidated Witness
- PTAB Invalidates Patent Claims For Pelvis Joint Treatment
- Johnson & Johnson Settles 161 Hernia Mesh Suits In Ga.
- Illumina Shareholders Oust Board Chair Amid Icahn Battle
- RI Sues 3M And DuPont Over PFAS Contamination
- Judge Lets Gout Drug Antitrust Suit Move Forward
- Shkreli Cos. Bankruptcy Illustrates Novel Subchapter V Trend
- Insurer Says No Coverage For $100M Lab Theft Dispute
- Gilead, Teva Ink 11th-Hour HIV Antitrust Deal With Pharmacies
- 3 Firms Lead Medtronic's $730M Buy Of Insulin Patch Maker
- Teva Says Feds Can't Bolster FCA Suit With Advisory Rulings
- Jurors Weren't Barred Over Race, Gilead Antitrust Judge Says
- BALCA Says FAQ Can't Be Used To Deny Foreign Worker App
- 8th Circ. Sends 'Non-Drowsy' Walmart Suit Back To Fed. Court
- Judge Lets Walgreens Try To Shift Some Overbilling Blame
- LegitScript Can't Pause Blacklist Suit, Court Told
- On Deck In JPML: FTX, Cheer Abuse, T-Mobile
- PTAB Axes 5 Patents Over Owner's 'Egregious Abuse'
- 3rd Circ. Urged To Revive Fosamax MDL
- Merck's $10.8B Calif. Biotech Buy Goes Unchallenged By FTC
- Fed. Circ. Splits On When Exactly A Catheter Was Invented
- Boston Scientific Downsizes Stent Deal Under FTC Pressure
- USPTO Wants Feedback On How To Curb Counterfeit Goods
- Swedish Rare Disease Pharma Biz Ends Takeover Talks
- Glaxo Gets Second Wind In Inhaler TM Revival Bid
- Janssen Prevails In Patent Battle With Mylan Over Generics
- Monsanto Wins Roundup Trial Brought By Gardener
- HIV Drug Antitrust Trial 'Leaving The Station,' Judge Says
- DOJ, Drug Buyers Rip Teva's Criminal Probe Doc Bid In MDL
- Delaware Jury Rejects Suit Alleging Overpayments To Rite Aid
- 4 Firms Steer Canadian Automation Firm's $275M US IPO Plan
- Dollar General Escapes Pain Patch Packaging Class Action
- Apple Says Masimo Can't Revive Biz Trade Secrets In IP Row
- Philips Owes $2.5M Treble Damages After IP Trial, Rival Says
- Bayer Beats Consumers' 'Vague' Benzene Contamination Suit
- Nurse Targets Chicago Hospitals Over Biometric Cabinets
- Janssen And Amgen Settle Patent Row Over Stelara Biosimilar
- Purdue Approved For OTC Biz Sale As Ch. 11 Case Drags On
- Biotech Co. Says Red Cross Plainly Violated Antitrust Law
- Walgreens Nears Settlement In Theranos MDL
- Ga. Judge Ends Most Claims In Ermi Whistleblower Suit
- A Lawyer's Guide To Approaching Digital Assets In Discovery
- In-House Labor Veteran Joins Seyfarth As Partner In NC
- Sandoz Sues To Invalidate Prostate Cancer Drug Patent
- What IP Attys Should Know About Enablement After Amgen
- Teva Accused Of Asthma Inhaler Antitrust Scheme
- Economic Claims Tossed From Abbott Formula MDL
- High Court's Ethics Statement Places Justices Above The Law
- DOJ Says Not To Toss FCA Case Against Hospital System
- Justices Won't Eye Rulings Over Hirshfeld PTAB Decisions
- Pharma Co. Hid Nonhuman Primate Imports, New Suit Says
- Walgreens Says Crowell 'Betrayal' Led To $642M Humana Win
- High Court Amgen Patent Ruling Promotes Medical Innovation
- Catching Up With Delaware's Chancery Court
- AstraZeneca Sales Reps Fight To Keep Pay Bias Suit Alive
- CureVac Lobs Infringement Counterclaims At BioNTech, Pfizer
- Ex-Amgen Exec's Startup Gets PTAB To Review Amgen Patent
- Walgreens Judge Warns SF $230M Opioid Deal No Candy Jar
- Monsanto Rep 'Always' Considered Roundup Safe, Jury Told
- Mylan Beats Most Claims In Investor Suit Over W.Va. Plant
- Bayer Investors Land Class Cert. Over Roundup Litigation
- Del. Court Rejects Tricida's Ch. 11 Plan, Citing Unfair Opt-Outs
- 1st Circ. Won't Revive J&J Hip Implant False Claims Act Suit
- White House Looks To Scrap CBP Worker's Vax Mandate Case
- Jury Clears Miami Drug Trial Co.'s CEO Of Fraud Charges
- Harvard Fights Vizgen's Claims In Spatial Imaging Patent Fight
- Dow Cancer Suits To Stay Separate Over Workers' Differences
- Time For Law Schools To Rethink Unsung Role Of Adjuncts
- IP Litigator Leaves Stroock For Venable In NY After 1 Year
- Fieldfisher Hires Cybersecurity Pro From Shoosmiths
- UK Litigation Roundup: Here's What You Missed In London
- Justices Clamp Down On Broad Patents In Amgen Decision
- Del. Court Trims Biotech Investors' Stock Transfer Suit
- Takeda Rejects $480M AbbVie Claim In Del. Drug Shortage Suit
- FDA Says More Than 250 E-Cig Products Can't Be Sold In US
- Takeaways From FTC's Challenge Of Amgen Deal
- Mich. Health System To Pay $800K To End Meal Break Suit
- Lab Can't Trim PerkinElmer's $6.3M COVID-19 Gear Suit
- DEA Affirms Denial Of Doctor's Bid To Reschedule Psilocybin
- Defending The Religious And Spiritual Use Of Psychedelics
- Prior Cases Bar Janssen Kickback FCA Claims, Judge Told
- Judge Denies Horse Assoc.'s Injunction Bid Pending Appeal
- Duo Says USCIS Keeps 'Unnecessary' $85 Biometric Fees
- What The Justices' Questions Signify For FCA Compliance
- Deals Rumor Mill: Manchester U, Ottawa Senators, Maravai
- Sanofi Wins Patent Enablement Fight At Supreme Court
- The First States Jumping Into Regulating Psychedelics
- 5th Circ. Needles FDA On Its Abortion Pill Approval Process
- Juul And Altria To Pay $60.5M In Minn. Youth Vaping Deal
- Chancery OKs Deal, $1.35M Atty Fee To End Drug Trial Suit
- 6th Circ. Won't Rethink FCA Hiring Case Decision
- Synthego Gets PTAB To Ax 2 Agilent CRISPR Patents
- FTC Adds CVS Unit, Another Group Purchaser To PBM Probe
- Ex-Immunomedics CFO Cops To Giving Stock Tip To Girlfriend
- CureVac Gets Pfizer COVID Vax Patent Fight Moved To Va.
- Elizabeth Holmes Gets New May 30 Self-Surrender Date
- Judge Won't Free Glove Maker From Forced Labor Suit, Yet
- Pa. Doctor, Pharmacy Sued For Over-Prescribing Medicines
- Tips For In-House Legal Leaders In A Challenging Economy
- Baker Botts Grows Singapore Office To 7-Lawyer Team
- Walgreens To Pay SF $230M After Landmark Opioid Trial Loss
- 6 Firms Build Canadian Biotech SPAC Merger
- 2nd Circ. Denies AstraZeneca Investors New Shot At Vax Suit
- Holmes Ordered To Prison, Hit With $452M Restitution
- NC Republicans Jettison Governor's Veto On Abortion Limits
- Tech, Drug Cos. Back Ban On AI As Inventor On Patents
- ITC To Partly Review Apple Watch Patent Decision
- Jazz Ducks BCBS Claims But Not Xyrem Class Cert.
- J&J's $8.9B Talc Deal Includes $400M To 6 States
- Tips For Drafting Paragraph IV Notice Letters
- NJ Panel Won't Revive Investor Suit Over Medical Co. IPO
- Proskauer Must Face Cut-And-Paste Malpractice Suit
- Nossaman Adds 2 Health Care Partners In Calif. Capital
- J&J Talc Unit Can Pursue Ch. 11 Plan During Dismissal Fight
- Psychedelics Companies Face Quandary In Protecting IP
- Crowell Nabs IP Atty Team With Disruptive Tech Experience
- FTC Challenges $28B Amgen-Horizon Therapeutics Merger
- Qualms With Abortion Can't Crush Pill Access, 5th Circ. Told
- What's Next For Patent Eligibility After Latest Denials?
- 2nd Circ. Backs Denial Of Fees For Former PixarBio Attys
- 9th Circ. Revives San Francisco Workers' Vax Mandate Fight
- Gilead HIV Drug Fight Begins Rare Summary Jury Trial
- Scorpion Venom Drug Biz Hit With SEC Fraud Suit
- Judge Affirms $490M FCA Verdict Against Medical Distributor
- Natera Nets $19M Verdict In Cancer Test Patent Case
- The Clinic Fighting For Patients' Right To Try Mushrooms
- Saudi Pharma Co. Eyes $336M IPO Steered By 4 Firms
- Justices Won't Take Up $39M Monsanto Cy Pres Settlement
- Judge OKs Ga. Manufacturer's Plan To Stop PFAS Pollution
- Catching Up With Delaware's Chancery Court
- A Fresh Look At The Jury Data In Waco Patent Trials
- Ravgen's Prenatal Test Patent Win Boosted To $372M
- Conn. Lab Fights Insurer Over $2.4M Tropical Storm Loss
- Firms To Seek $2M For Pharma Suit Settlement In Del.
- Pension Fund Wants To Lead $10B Amgen Tax Dispute
- What Associates Need To Know Before Switching Law Firms
- High Court Refuses To Hear 'Skinny Label' Drug Patent Case
- Insys Trustee Says Court Should Halt Insurance Coverage Suit
- Wash. Fish Health Co. Broke Deal, Chilean Distributor Says
- Gardener Rests Roundup Case After Telling Of Cancer Pain
- Biotech Co. Wants Chubb Unit's $3M Fire Suit Tossed Again
- FTC Says Horse Association Bid For Injunction Will Likely Fail
- FDA Won't Approve 6,500 E-Cigs For US Market
- Moderna Fires Back At Rival's 'Baseless' Vaccine Patent Row
- How Fed. Circ. Is Applying Section 101 To Drug Patents
- Talc Victims Seek Right To Sue J&J Over Voided Funding Deal
- NephroSant Founder's Chancery Redaction Bid Is Rejected
- UK Litigation Roundup: Here's What You Missed In London
- Taxation With Representation: Gibson Dunn, Davis Polk
- A Case For Sharing Mediation Statements With Counterparties
- Companies Explore Costly Capital-Raising Ideas Amid Slump
- Altria's Vaping Claims Deal Could Spur Other Settlements
- Philips Inks $62M Deal Resolving FCPA Allegations From SEC
- SmileDirectClub Asks 9th Circ. To Seal Invisalign Co.'s Suit
- Senate Panel Approves Bipartisan PBM Overhaul
- Ohio Opioid Settlement Foundation Must Make Records Public
- DOJ Sanctioned In FCA Case Over Discovery Dispute
- Second Investor Rebels Against Aurinia Pharmaceutical Board
- Tackling Long-Tail Legacy Liability Risk: A Defendant's Toolkit
- Indivior Wants Class Tossed From Suboxone Antitrust Case
- Challenging Standing In Antitrust Class Actions: Injury-In-Fact
- Ex-IRS Officer Led $3M Pandemic Loan Scam, Feds Say
- NC Contractor Jilted Ohio Corp. On $15M Project, Suit Says
- Reupped Bill Pushes Review Of Outbound China Investments
- Astellas, Scientists Settle Stem Cell Patent Inventorship Fight
- Fortis Rips J&J's Bid To DQ Selendy Gay In Chancery Case
- What COVID Vaccines May Reveal About SEPs Amid Crisis
- Deals Rumor Mill: Saudi Aramco, Alibaba, Meta
- Del. Judge Says InterMune Doesn't Have To Indemnify Ex-CEO
- Lack Of HIV Drug Deal Before Trial Shocks Antitrust Judge
- Biotech Co. Facing Third Contempt Says It Misread Order
- LegitScript Renews Bid To Pause Price Check Blacklist Suit
- Jeb Bush-Led SPAC Fails To Find Merger Partner
- To Gets Vaccine Bundling Suit Tossed, Merck Points To GSK
- Roundup Cases Need To Move, Mo. High Court Hears
- Fed. Circ. Won't Review Dartmouth's Milk Vitamin Patent Loss
- Judge Greenlights Claim Over 'Extra Strength' Vitamin C
- SEC Says Medical Device Co. Duped Investor In $730K Deal
- FCA Chases 'Shrewder' Kickbacks As 50-Year Hunt Intensifies
- Investor Can't Undo $155M Lubricant Co. Acquisition, For Now
- Working From Home? Beware Insider Trading, Tipping Risks
- Fed. Circ. Won't Revive Vanda's Sleep Disorder Patent Claims
- Preparing For Legal Scrutiny Of Data Retention Policies
- FDA Panel Votes For OTC Birth Control Pill
- Altria Strikes $235M Deal To End Youth Vaping Claims
- Fujifilm To Buy Entegris Electronic Chemicals Biz For $700M
- Convicted 'Pharma Bro' Shkreli's Companies File For Ch. 11
- Biz Groups Again Push For Litigation Funding Disclosure Rule
- Eli Lilly Drug Rebate Damages Tripled To $183M
- Roundup Was Likely Cause Of Plaintiff's Cancer, Jury Hears
- Dow, PPG Can't Escape Punitives In Calif. Contamination Suit
- SF Schools Need $92M For Vaping Fix, Altria Jury Told
- FDA's 'Radical' Abortion Pill Stance Fails, 5th Circ. Told
- Treasury Blacklists 4th 'Chapito,' Cartel 'Super Lab' Head
- Proskauer Eyes Early Win In Copy-Paste Malpractice Suit
- Fed. Circ. Says PTAB Wrongly Sunk Sanofi Injector Pen Patent
- DEA Extends Telehealth Rule For Controlled Substances Rx
- Congress Must Reform PBMs To Lower The Cost Of Insulin
- 3rd Circ. Won't Revive J&J Investors' Arbitration Proposal Suit
- Niaspan Buyers Ask 3rd Circ. For Rehearing On Class Cert.
- Ga. City, Manufacturer Agree To Stop PFAS Pollution
- HHS Urges Court To Toss Texas Abortion Pill Suit
- Fed. Circ. Ruling Can Serve To Guide Patent Range Claims
- Ex-Allen & Overy IP Atty Joins Duane Morris In Silicon Valley
- FTC's Framework For Assessing Direct Selling Cos. Is Flawed
- 3rd Circ. Says J&J Talc Unit's Ch. 11 Should Proceed
- Jury Rejects Feds' Claims Gilead Infringed HIV Drug Patents
- Altria Fueled Juul Vaping Crisis, Harvard Prof. Testifies
- Pfizer Spinoff Sued By Former Vax Supplier
- FDA Hit With Suit Looking To Keep Abortion Drug Access
- Talc Co. Tells 3rd Circ. Ch. 11 Mandamus Writ Is Premature
- ITC Looking Into China, Taiwan Drug Device Imports
- PE Firms To Pay $4.25B For Baxter's BioPharma Solutions Biz
- Illumina Tells Shareholders Icahn Wrong About Selling Grail
- Paul Weiss' Veeraraghavan On Slew Of Health Care Deals
- Dope Seller Cops To Supplying Olympic Sprinter Before Tokyo
- Astellas, Aon Strike Deal In 401(k) Management Class Action
- Director Exits Cancer Drug Co. Following Farallon Pressure
- Attorneys Should Have An Ethical Duty To Advance DEI
- Catching Up With Delaware's Chancery Court
- Del. Justices Order Chancery Review Of Yanked Stock Grants
- Walgreens To Face Theranos MDL, Escapes Punitive Claims
- Joint Juice Maker Rips Class Attys' 'Overstated' $8.3M Fee Bid
- 3rd Circ. Upholds Class Cert. Denial In Niaspan MDL
- Roundup User's Lymphoma Journey 'Not The Norm,' Jury Told
- 8th Circ. Upholds Conviction Of Ex-Monsanto Scientist
- Stryker Settles Faulty Spinal Device Claims Days Before Trial
- Judge Won't Rethink Injunction In Idaho Abortion Law Suit
- Kenvue's IPO Offers Glimmer Of Hope During Bleak Times
- Drug Co. Wants Houston Judge To Halt Opioid MDL Discovery
- FDA Alum And Regulatory Pro Joins Walmart Legal Team
- Ohio Hospital Wants Nurses' Unpaid OT Suit Nixed
- New Considerations In Med Device Cybersecurity Compliance
- Texas Panel Won't Re-Freeze Gilead Medicaid Fraud Suit
- Fed. Circ. Vacates PTAB Ax Of Guardant DNA Test Patent
- NC Town Sues 30 Cos. Alleging 'Forever Chemicals' Pollution
- Geron Investors Report No Objections To $1.35M Atty Fee Bid
- Health Hires: Blank Rome, Husch Blackwell
- Titan Of The Plaintiffs Bar: Motley Rice's Joe Rice
- Data-Driven Insights Are Key To Attracting Today's Clients
- Taxation With Representation: Wachtell, Kirkland, Fried
- UK Litigation Roundup: Here's What You Missed In London
- Apple, Masimo Denied JMOL Wins In $1.85B Watch IP Row
- NC's 12-Week Abortion Ban Passes Both State Chambers
- 4th Circ. Tests Walgreens' Bid To Skip Medicaid Fraud Liability
- 11th Circ. Urged To Rethink Nix Of $8M Supplement Deal
- BioTech Co. Must Prove It Didn't Flout Court Order In SEC Suit
- Cooley, Davis Polk Steer Biotech Firm's Upsized $540M IPO
- Lannett Seeking Fast Run Through $600M Reorg
- Full Fed. Circ. Won't Rethink Decision On Heart Drug IP
- Biopharm Co. Sued In Del. Over Consent Right Ban
- Federal Oversight Of AI In Healthcare Is Taking Shape
- Deals Rumor Mill: Pfizer, Subway, SoftBank
- Kroger Strikes $68M Deal To Avoid Trial In W.Va. Opioid Suit
- Buchanan Ingersoll Gets $700K In Fee Dispute With Ex-Client
- Altria Accused Of 'Pseudo Social Responsibility' At Trial
- Ex-FDA Officials Back Feds In Abortion Pill Fight At 5th Circ.
- Judge Cuts Disgorgement Ex-Atty Owes SEC In Fraud Case
- North Carolina House Approves 12-Week Abortion Ban
- Dismissal Motion Hearing Set For June In J&J Talc Ch. 11
- 4 Firms Lead Regentis Biomaterials In $95M SPAC Merger
- W. Va. Abortion Drug Law Fight Can Continue, Judge Rules
- Stryker Hires Counsel To Launch New Internal FCPA Probe
- GSA Botched Bid Review In $238M Storage Row, GAO Says
- Ohio Businessman Admits Role In $24M Health Fraud
- Ghosting In BigLaw: Why Better Feedback Habits Are Needed
- 'Extortion' Charge Roils FCA Bar As Kickback Suits Surge
- Tenn. Eye Center To Pay $17M To Settle Kickback Claims
- Ex-Juul COO Says He Was Fired After Raising Teen User Fears
- Wis. High Court Won't Force Hospital To Use Ivermectin
- Reject 'Carte Blanche' For Risky Opioid Sales, 4th Circ. Urged
- Biotech Co. Can't Ax Beefed Up IP Theft Claims Before Trial
- Stanford Urges High Court To Take 'Ideal' Patent Law Case
- Talc Claimants Ask 3rd Circ. To End J&J Unit's New Ch. 11
- Sandoz Drops Counterclaims After $39M Patent Trial Loss
- Essential Oils False Ad Suit Revived By 2nd Circ.
- DuPont To Buy Spectrum Plastics Group From AEA For $1.75B
- 1st Circ. Receptive To Reviving Rx Delivery Data Breach Suit
- NJ Jury Sides With J&J Unit In Pelvic Mesh Injury Suit
- Activist Investor Nominates 2 Candidates For Masimo Board
- Juul Investor Concedes Family's Vaping Concerns At Trial
- 'Momentous Day' As Justices Eye Chevron Deference Demise
- Humana, Aetna Say Calif. Law Bars Drugmaker's Fed. Court Bid
- Amazon Patent Evaluators Are Biased, Lawsuit Says
- NC Couple Drops 3M, Others From Asbestos Cancer Suit
- DC Circ. Asks What's Wrong With Endo-Impax Deal
- Drugmaker Lannett Strikes Deal On $511M Debt Restructure
- Judge Wary Of Economic Claims In Abbott Formula MDL
- Mistrial Declared In Masimo's $1.85B IP Fight Against Apple
- Biotech Investor Makes 2nd Push For $1.4M Deal Approval
- Biotech Co. To Face Amended Investor Suit Over COVID Test
- Chinese Carbon Cos. Dealt Back-To-Back Losses In Duty Row
- Arrayit Exec Denied New Trial In COVID Test Fraud Case
- Examining Chancery's Recent Openness To Caremark Claims
- Catching Up With Delaware's Chancery Court
- Brown Rudnick's NY Office Picks Up Drug Patent Pro
- Don't Let Gov't Read Law Into Obscurity, Arthrex Says
- NJ Appeals Panel Upholds Merck's $1.4B Cyber Coverage Win
- Law Needs A Balance Between Humanism And Formalism
- Titans Of The Plaintiffs Bar: Bleichmar Fonti's Name Partners
- Cooley-Led Biotech Firm Launches Plans For $350M IPO
- 9th Circ. Asked To Rethink Stem Cell Injury Coverage Ruling